Gilead Sciences, Inc. $GILD Stock Position Cut by Polaris Capital Management LLC

Polaris Capital Management LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.7% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 324,900 shares of the biopharmaceutical company’s stock after selling 34,800 shares during the period. Gilead Sciences accounts for 2.4% of Polaris Capital Management LLC’s portfolio, making the stock its 11th biggest holding. Polaris Capital Management LLC’s holdings in Gilead Sciences were worth $36,022,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of GILD. Brighton Jones LLC boosted its position in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares in the last quarter. Bison Wealth LLC bought a new position in shares of Gilead Sciences during the 4th quarter valued at about $215,000. Hennion & Walsh Asset Management Inc. boosted its position in shares of Gilead Sciences by 10.2% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 12,380 shares of the biopharmaceutical company’s stock valued at $1,387,000 after purchasing an additional 1,143 shares in the last quarter. Matrix Trust Co boosted its position in shares of Gilead Sciences by 12.9% during the 1st quarter. Matrix Trust Co now owns 1,188 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 136 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. boosted its position in shares of Gilead Sciences by 113.7% during the 1st quarter. Thurston Springer Miller Herd & Titak Inc. now owns 483 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 257 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $112.69 on Friday. Gilead Sciences, Inc. has a 12-month low of $83.98 and a 12-month high of $121.83. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The business’s 50-day moving average price is $114.34 and its two-hundred day moving average price is $109.92. The stock has a market cap of $139.83 billion, a PE ratio of 22.45, a P/E/G ratio of 0.75 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. During the same quarter in the previous year, the business posted $2.01 earnings per share. The business’s revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 62.95%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on GILD shares. Daiwa America upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective for the company in a research report on Tuesday, August 19th. UBS Group raised their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Needham & Company LLC upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective for the company in a research report on Friday, July 25th. Finally, Dbs Bank upgraded shares of Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Three research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $117.17.

Insider Activity

In other news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $340,710.00. Following the sale, the insider directly owned 113,193 shares of the company’s stock, valued at approximately $12,855,329.01. This trade represents a 2.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $111.66, for a total value of $1,116,600.00. Following the sale, the chief executive officer directly owned 591,203 shares in the company, valued at $66,013,726.98. The trade was a 1.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 82,000 shares of company stock valued at $9,402,130. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.